Prelude Therapeutics advances toward clinical trials for first-in-class oral KAT6A degrader following FDA IND clearance
Executive summary: The FDA cleared Prelude Therapeutics' IND application for PRT13722, an oral KAT6A selective degrader. This clearance enables the company to move its lead candidate into Phase 1 human clinical trials for HR+ breast cancer.
Who is involved: Prelude Therapeutics and the U.S. Food and Drug Administration (FDA).
Likely next: Commencement of patient enrollment for the Phase 1 study, expected in Q4 2026.
Prelude Therapeutics has successfully obtained FDA clearance for its Investigational New Drug application for PRT13722, marking a critical regulatory milestone. The company is now positioned to initiate Phase 1 clinical testing for this oral KAT6A selective degrader, specifically targeting HR+ breast cancer patients. This development represents a transition from preclinical research to human clinical evaluation for a novel therapeutic modality.
What's next — scenarios
Base: Successful Phase 1 enrollment (70%)
Prelude meets its Q4 2026 target, maintaining investor confidence and clinical timelines.
- Confirmation of first patient enrolled in Q4 2026
Downside: Clinical delays (20%)
Enrollment fails to meet Q4 2026 targets due to recruitment or logistical hurdles, delaying data readout.
- Delayed patient enrollment updates in early 2027
Upside: Early safety signals (10%)
Positive initial safety data accelerates interest from potential biopharma partners.
- Interim safety report published post-enrollment
What to watch
- Patient enrollment progress in Q4 2026
- Updates on PRT13722 safety and tolerability profiles during Phase 1
Timeline
- — Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader. (GlobeNewswire)
- — Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy (PR Newswire)
- — Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate (PR Newswire)
Analysis — what this means
Likely next events
- Start of patient enrollment for PRT13722 Phase 1 study in Q4 2026
Sectors affected
- Oncology therapeutics
- Biopharmaceutical R&D
- Drug discovery services
Regulatory implications
- Compliance with FDA IND protocols for Phase 1 safety monitoring
Historical parallels
- Alebund Pharmaceuticals FDA IND clearance for AP308 (Sept 2026)
- Acepodia FDA IND clearance for ACE723 (Sept 2026)
Key entities
Sources
- Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader. — GlobeNewswire
- Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy — PR Newswire
- Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate — PR Newswire
Related cases
- Capricor Therapeutics faces growing legal pressure as investors approach deadline for class action leadership amidst FDA review uncertainties
- Outlook Therapeutics focuses on commercializing LYTENAVA following FDA regulatory milestones
- CraniUS Therapeutics secures FDA 510(k) clearance for its patient-specific cranial implant platform
- Opus Genetics advances OPGx-BEST1 toward Phase 3 after positive low-dose clinical data and successful FDA alignment
- Alebund Pharmaceuticals gains FDA clearance to initiate clinical trials for IgA nephropathy treatment
- Karmanos Cancer Institute begins offering the newly FDA‑approved KRAS G12C inhibitor daraxonrasib (Rasonque) for metastatic pancreatic cancer, marking the first clinical rollout of a targeted therapy for a historically hard‑to‑treat malignancy